Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05462106 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
A Phase 1 study of Alzheimers Disease and Prodromal Alzheimer's Disease, sponsored by AC Immune.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 176
- Enrollment target
- 19
- Study locations
NCT05462106: Recruiting Phase 1 study of Alzheimers Disease and Prodromal Alzheimer's Disease, sponsored by AC Immune.
NCT05462106 is a Phase 1 study of Alzheimers Disease and Prodromal Alzheimer's Disease that is actively recruiting participants, run by AC Immune. The registered enrollment target is 176 participants, below the 3,925-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (96% lower). The trial reports 19 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05462106, a Phase 1 study of Alzheimers Disease and Prodromal Alzheimer's Disease, is actively recruiting participants, sponsored by AC Immune.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 176 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL ACI-24.060 at Dose A
- BIOLOGICAL ACI-24.060 at Dose B
- BIOLOGICAL ACI-24.060 at Dose C
- BIOLOGICAL ACI-24.060 at Dose D
Study Locations (19)
Other
- Fundació ACE, Institut Català de Neurociències Aplicades - Barcelona
- Hospital de la Santa Creu i Sant Pau - Barcelona
- Hospital Universitario Virgen De Las Nieves - Granada
- Hospital Clínico San Carlos - Madrid
- Hospital Universitario de la Princesa - Madrid
- Hospital Universitario Marqués de Valdecilla - Santander
- Hospital Universitario y Politécnico La Fe - Valencia
- Cambridge and Peterborough NHS Foundation Trust - Windsor Research Units - Cambridge
- Liverpool University Hospitals NHS Foundation Trust - Liverpool
- Re:Cognition Health Limited - London
- South London and Maudsley NHS Foundation Trust of The Maudsley Hospital - London
- Oxford Health NHS Foundation Trust - Oxford
Arizona
- Barrow Neurological Institute - Phoenix
Indiana
- Indiana University / IU Health - Indianapolis
Kansas
- University of Kansas Medical Center Research Institute - Fairway
Massachusetts
- Massachusetts General Hospital - Boston
Missouri
- The Washington University - St Louis
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- UT Health San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2022-06-21 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
What NCT05462106 shows while recruiting
NCT05462106 is an interventional study that assigns participants to a tested intervention. The registered 176 participants enrollment target is mid-sized for trials with a published cap, below the 3,925-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (96% lower).
The record links to 5 conditions, with Alzheimers Disease appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT05462106 lists 19 locations in 8 states (Other, Arizona, Indiana).
Frequently Asked Questions
What is clinical trial NCT05462106 about?
NCT05462106 is a clinical study titled "A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)". The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
What is the current status of trial NCT05462106?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 176 participants. The study started on 2022-06-21. Estimated completion is 2026-06.
What conditions does trial NCT05462106 study?
This clinical trial studies the following conditions: Alzheimers Disease, Prodromal Alzheimer's Disease, Amyloid Plaque, Beta-Amyloid, DSAD.
What interventions are being tested in trial NCT05462106?
The interventions under investigation include: Placebo (BIOLOGICAL), ACI-24.060 at Dose A (BIOLOGICAL), ACI-24.060 at Dose B (BIOLOGICAL), ACI-24.060 at Dose C (BIOLOGICAL), ACI-24.060 at Dose D (BIOLOGICAL).
Who is sponsoring clinical trial NCT05462106?
This trial is sponsored by AC Immune, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05462106 being conducted?
This trial has 19 study locations across Arizona, Indiana, Kansas, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05462106's enrollment target sits among peer trials
176 65th of 147 higher than 83 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
RECRUITING · Phase 1
-
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
RECRUITING · Phase 1
-
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
RECRUITING · Phase 1
-
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
RECRUITING · Phase 1
-
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03304821 · 176 participants · Phase 2
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
- NCT03447938 · 176 participants · NA
The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial
- NCT03824145 · 176 participants · NA
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
- NCT04177914 · 176 participants · Phase 3
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI